Mannatech, Incorporated (MTEX) is a Texas-based wellness company that formulates and sells nutritional supplements, topical and skin care products, and weight-management and fitness products. Founded in 1993 and listed on Nasdaq, the company has built its brand around "glyconutrients" and other plant-derived ingredients that it markets as supporting overall health. I follow Mannatech as a niche, small-cap player in the global health and wellness sector, where its international footprint and proprietary formulations stand out.
Mannatech was incorporated in November 1993 and is headquartered in Flower Mound, Texas. The company traces its early history to the name Emprise International and was co-founded by Samuel L. Caster and Marlin Ray Robbins. Mannatech has grown from a U.S.-focused supplement business into an international operation spanning approximately 25 countries across three reporting regions: the Americas, EMEA, and Asia/Pacific. In mainland China, the company operates a distinct cross-border e-commerce model through its Meitai subsidiary rather than a traditional direct-selling network. When I looked into the background, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Mannatech's portfolio is organized around several product categories. Its Integrative Health line features daily nutritional supplements, while its Targeted Health and Essentials lines address specific wellness goals. The company also offers Weight and Fitness products and a Skin Care line built around Korean beauty ("K-Beauty") principles. Many offerings are built on proprietary ingredients such as the Ambrotose complex, Manapol powder, and other plant-derived nutrients.
The company's business model is primarily a direct-selling, or network-marketing, structure. Independent distributors, referred to as associates, purchase products at wholesale prices and earn commissions and incentives based on their sales and the sales of associates they recruit. Mannatech also sells directly to "preferred customers" and increasingly through e-commerce channels. This model means revenue depends heavily on the productivity and retention of its associate network, in addition to consumer demand for its products.
Substantially all of Mannatech's revenue comes from product sales to associates and preferred customers, supplemented by associate registration fees in certain markets. A meaningful share of sales is concentrated in a handful of flagship products, including its Ambrotose Life, TruHealth, and Optimal Support Packets lines. Geographically, the company competes in a crowded field of nutritional supplement and personal-care providers, ranging from large multinational direct sellers to mainstream consumer-health brands. Within the small-cap health technology space, Mannatech occupies a relatively small niche defined by its proprietary glyconutrient-based formulations and its loyal associate community.
Investors monitor Mannatech primarily for its exposure to the long-term growth of the global wellness and dietary supplement market. The company's proprietary ingredients and patents provide some degree of product differentiation that larger, more generic supplement brands may lack. Its international footprint—particularly its cross-border e-commerce presence in China and its established networks in Asia/Pacific markets such as South Korea and Japan—offers diversification beyond a single geography. For shareholders, the company's small size means its financial profile can shift meaningfully with relatively modest changes in revenue, associate activity, or expense discipline, which can make the stock especially sensitive to operational execution. From what I see, this sensitivity is worth watching closely.
Before considering MTEX, investors should weigh several factors. The company's reliance on a network-marketing distribution model exposes it to regulatory scrutiny of direct-selling practices in multiple jurisdictions, as well as the challenge of consistently recruiting and retaining active distributors. The nutritional supplement and personal-care industries are highly competitive and subject to evolving product-safety and labeling regulations. Mannatech is also a relatively small company, which can make its results more volatile and its stock less liquid than larger peers. Finally, the business is sensitive to foreign-exchange movements and regional economic conditions given its substantial international operations.
In my analysis of companies like this, I often turn to Tickeron’s AI Screener to quickly compare fundamentals and technical signals across the sector. It helps surface ideas that align with a focused investment approach without replacing deeper due diligence.
Mannatech stands out as a small, internationally diversified wellness company built on proprietary, plant-derived ingredients and a direct-selling distribution network. Its combination of niche product science, a global associate base, and exposure to the growing supplement market keeps it relevant for investors who follow the health and wellness industry—while its modest size and model-specific risks make it best understood as a specialized holding within the broader consumer-health landscape.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The 10-day moving average for MTEX crossed bearishly below the 50-day moving average on November 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MTEX as a result. In 96 of 117 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for MTEX turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 46 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
MTEX moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MTEX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where MTEX advanced for three days, in 136 of 185 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
MTEX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 108 of 122 cases where MTEX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MTEX's P/B Ratio (-3.149) is slightly lower than the industry average of (3.045). P/E Ratio (-2.074) is within average values for comparable stocks, (55.291). Projected Growth (PEG Ratio) (0.130) is also within normal values, averaging (0.741). MTEX's Dividend Yield (0.099) is considerably higher than the industry average of (0.015). P/S Ratio (0.139) is also within normal values, averaging (0.357).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. MTEX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MTEX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 68, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of nutritional supplements, topical products, and weight-management products
Industry FoodDistributors